HEPATOCELLULAR CARCINOMA IN CIRRHOSIS: WARD ROUND PRESENTATION
For a patient with HCC arising in cirrhosis, focus your ward round presentation on identifying stigmata of chronic liver disease, assessing liver function (Child-Pugh status), evaluating portal hypertension, and determining tumor burden to guide treatment allocation using the BCLC staging system 1, 2.
PATHOPHYSIOLOGY
HCC develops through a well-defined carcinogenesis pathway in cirrhotic livers. Chronic inflammation, fibrogenesis, and immune dysregulation create a prooncogenic microenvironment that promotes genomic instability and malignant transformation 3. The progression follows: chronic liver injury → regenerative nodules → low-grade dysplastic nodules → high-grade dysplastic nodules → early HCC → advanced HCC. Through this progression, there is development of arterial neovascularization which becomes the dominant blood supply, replacing normal portal venous supply 4. This arterial hypervascularization forms the basis for radiological diagnosis.
CHIEF COMPLAINTS
Patients typically present with:
- Right upper quadrant pain (dull, aching character) 5
- Abdominal distension (from ascites or hepatomegaly)
- Weight loss and anorexia
- Jaundice (in decompensated disease)
- Hematemesis or melena (from variceal bleeding)
- Many patients are asymptomatic, detected through surveillance programs 4
HISTORY TAKING
Risk Factors for Chronic Liver Disease
- Viral hepatitis: HBV, HCV status and treatment history 4
- Alcohol intake: quantity, duration, current use 4
- Intravenous drug use 4
- Metabolic factors: obesity, diabetes, MASLD 6, 7
- Other: hemochromatosis, autoimmune hepatitis, primary biliary cirrhosis 8
Performance Status
- ECOG performance status (0-4 scale)
- Nutritional state: recent weight loss, muscle wasting 4
REVIEW OF SYSTEMS
Focus on complications of cirrhosis and portal hypertension:
- Gastrointestinal: hematemesis, melena, early satiety, abdominal distension
- Neurological: confusion, altered sleep-wake cycle, asterixis (hepatic encephalopathy)
- Constitutional: fever, night sweats, weight loss, fatigue
- Respiratory: dyspnea (hepatopulmonary syndrome, pleural effusion)
- Genitourinary: decreased urine output, dark urine
GENERAL EXAMINATION
Vital Signs
- Blood pressure, heart rate, temperature, respiratory rate
- Look for hypotension (hepatorenal syndrome, variceal bleeding)
Nutritional Assessment
- Muscle wasting (temporal wasting, reduced muscle bulk)
- Cachexia (advanced disease)
- Body mass index
Stigmata of Chronic Liver Disease
- Jaundice (scleral icterus, skin)
- Spider angiomata (upper body distribution)
- Palmar erythema
- Gynecomastia
- Testicular atrophy
- Parotid enlargement
- Dupuytren's contracture (alcohol-related)
- Leukonychia (white nails)
- Clubbing
- Asterixis (hepatic encephalopathy)
- Fetor hepaticus
SYSTEMIC EXAMINATION
Abdominal Examination
Inspection:
- Distension (ascites, hepatomegaly)
- Dilated superficial veins (caput medusae)
- Surgical scars
- Umbilical hernia
Palpation:
- Hepatomegaly with nodular, irregular surface 5
- Splenomegaly (portal hypertension) 4
- Ascites (shifting dullness, fluid thrill) 4
- Tender hepatic mass (occasionally palpable)
Percussion:
- Liver span
- Ascites assessment
Auscultation:
- Hepatic bruit (rare, suggests HCC)
- Venous hum (portal hypertension)
Other Systems
- Cardiovascular: signs of high-output state
- Respiratory: reduced breath sounds at bases (pleural effusion)
- Neurological: mental status, asterixis, peripheral neuropathy
DIAGNOSIS
Laboratory Analysis
Liver Function Tests:
Etiology Assessment:
- HBsAg, anti-HBc, HBV DNA 4
- Anti-HCV, HCV RNA 4
- Iron studies (ferritin, transferrin saturation) 4
- Autoimmune markers (ANA, ASMA, immunoglobulins) 4
Hematology:
- Platelets (thrombocytopenia suggests portal hypertension) 4
- Complete blood count
Tumor Marker:
Renal Function:
- Creatinine, electrolytes (assess for hepatorenal syndrome)
Imaging Studies
For Diagnosis and Staging:
Nodules >1 cm detected on surveillance ultrasound require:
- Dynamic multiphasic CT (arterial, portal venous, delayed phases) OR
- Dynamic contrast-enhanced MRI (with extracellular or hepatobiliary contrast) 4, 1, 4
Diagnostic hallmark: Arterial phase hyperenhancement (APHE) with washout in portal venous or delayed phases 4, 1, 4, 2
For nodules >2 cm: One positive imaging technique showing typical vascular pattern is sufficient for diagnosis in cirrhotic patients 10, 9
For nodules 1-2 cm: Two concordant imaging techniques showing typical pattern OR biopsy if atypical 10, 9
For nodules <1 cm: Follow with ultrasound every 3-4 months; if stable for 12 months, return to routine surveillance 1, 10
Staging Imaging:
Assessment of Portal Hypertension
Essential for treatment planning:
- Upper endoscopy: esophageal/gastric varices, portal hypertensive gastropathy 4
- Optional: Transjugular hepatic venous pressure gradient measurement 4
- Clinical signs: splenomegaly, thrombocytopenia (<100,000), varices 2
Liver Biopsy
Indications for biopsy 4, 1, 2:
- Atypical imaging features (no APHE or no washout)
- Non-cirrhotic liver
- Systemic therapy being considered (for molecular profiling)
- Nodules 1-2 cm with discordant imaging
Contraindications to biopsy 4:
- Patient not candidate for any therapy due to comorbidity
- Decompensated cirrhosis on transplant waiting list
- Candidate for resection with acceptable risk (biopsy unnecessary)
Risks: Tumor seeding (0-11%, median 17 months), bleeding (severe 0.5%, mild 3-4%) 1
DIFFERENTIAL DIAGNOSES
Primary Considerations
- Hepatocellular carcinoma (most common in cirrhosis)
- Intrahepatic cholangiocarcinoma (2-5% of nodules in cirrhosis; shows early washout <60s on CEUS) 11
- Combined hepatocellular-cholangiocarcinoma 2
- High-grade dysplastic nodule (premalignant; no stromal invasion) 4
Secondary Considerations
- Metastatic disease (colorectal, breast, lung, melanoma)
- Regenerative nodule (benign; no arterial hypervascularity)
- Focal nodular hyperplasia (rare in cirrhosis)
- Hepatic adenoma (rare; can transform to HCC) 4
- Hemangioma (peripheral nodular enhancement, centripetal fill-in)
- Abscess (pyogenic or amebic; clinical context important)
STAGING
Use the Barcelona Clinic Liver Cancer (BCLC) staging system 1, 4, 2. This integrates:
- Tumor burden (number, size, vascular invasion, extrahepatic spread)
- Liver function (Child-Pugh score)
- Portal hypertension (presence/absence)
- Performance status (ECOG)
BCLC Stages:
- Stage 0 (Very early): Single <2 cm, Child-Pugh A, PS 0
- Stage A (Early): Single or ≤3 nodules <3 cm, Child-Pugh A-B, PS 0
- Stage B (Intermediate): Multinodular, Child-Pugh A-B, PS 0
- Stage C (Advanced): Vascular invasion or extrahepatic spread, Child-Pugh A-B, PS 1-2
- Stage D (Terminal): Child-Pugh C or PS >2
INVESTIGATIONS SUMMARY
Initial workup for suspected HCC 4:
- History: Risk factors (HBV, HCV, alcohol, MASLD), symptoms of liver disease, performance status
- Examination: Stigmata of cirrhosis, jaundice, ascites, encephalopathy, splenomegaly, hepatomegaly
- Laboratory: Liver function (PT/INR, albumin, bilirubin), etiology (HBV, HCV, iron, autoimmune), platelets, AFP
- Imaging: Dynamic CT or MRI (diagnosis and tumor extent), chest CT (advanced disease), bone scan (symptomatic)
- Endoscopy: Upper endoscopy for varices/portal hypertensive gastropathy
- Optional: Hepatic venous pressure gradient, liver biopsy (if atypical)
MANAGEMENT
Treatment Allocation by BCLC Stage
BCLC Stage 0 and A (Early HCC) 4, 2:
First-line curative options:
- Liver transplantation: Preferred for decompensated cirrhosis (Child-Pugh B-C) with tumor within Milan criteria (single ≤5 cm or ≤3 nodules ≤3 cm) 8, 4
- Surgical resection: For single tumors, Child-Pugh A, no clinically significant portal hypertension (normal bilirubin, platelet >100,000, no varices, HVPG <10 mmHg), adequate future liver remnant 4, 2
- Radiofrequency ablation (RFA) or percutaneous ethanol injection (PEI): For tumors <3 cm, especially peripheral lesions; RFA preferred over PEI 8, 4
BCLC Stage B (Intermediate) 4, 2:
- Transarterial chemoembolization (TACE): First-line for multinodular disease, preserved liver function (Child-Pugh A-B), no vascular invasion, no extrahepatic spread
- Systemic therapy:
- First-line: Atezolizumab + bevacizumab (if no contraindications to bevacizumab)
- Alternatives: Sorafenib, lenvatinib
- Consider locoregional therapy in selected cases
BCLC Stage D (Terminal) 4:
- Best supportive care: Symptom management, palliative care involvement
Management of Cirrhosis Complications
Critical for expanding treatment options 12:
Ascites:
- Sodium restriction (<2 g/day)
- Diuretics (spironolactone ± furosemide)
- Large-volume paracentesis with albumin replacement
- Consider TIPS for refractory ascites
Hepatic Encephalopathy:
- Lactulose (target 2-3 soft stools/day)
- Rifaximin
- Identify and treat precipitants (infection, GI bleeding, constipation, medications)
Variceal Bleeding:
- Primary prophylaxis: Non-selective beta-blockers (propranolol, carvedilol) or endoscopic variceal ligation
- Acute bleeding: Octreotide, endoscopic therapy, antibiotics (ceftriaxone)
- Secondary prophylaxis: Beta-blockers + endoscopic ligation
Hepatorenal Syndrome:
- Volume expansion with albumin
- Vasoconstrictors (terlipressin, midodrine + octreotide)
- Consider TIPS or transplant evaluation
Multidisciplinary Team Approach
- Hepatologist
- Hepatobiliary surgeon
- Transplant surgeon
- Interventional radiologist
- Medical oncologist
- Liver pathologist
- Palliative care specialist
Surveillance After Treatment
For patients achieving complete response:
- Dynamic imaging (CT or MRI) every 3 months for first year, then every 3-6 months 4
- AFP monitoring
- Continue surveillance for new HCC development
Common Pitfalls
Not assessing portal hypertension before resection: Clinically significant portal hypertension is a contraindication to resection due to high decompensation risk 4, 2
Biopsying resectable lesions: Risks tumor seeding without changing management 4, 1
Using single-phase CT or non-dynamic imaging: Cannot diagnose HCC without arterial and portal venous phases 4, 1
Ignoring liver function in treatment decisions: Child-Pugh score and MELD are critical for determining candidacy for all therapies 2
Applying non-invasive criteria to non-cirrhotic livers: These criteria only validated in cirrhosis; biopsy required otherwise 1, 11, 2
Treating HCC without addressing cirrhosis complications: Uncontrolled ascites, encephalopathy, or varices limit treatment options and worsen outcomes 12